“So the studies have initiated and we would anticipate next year starting to see early data readouts.”

In context

“n significant positive momentum in BOTOX share in China as well as positive share in filler. So it's a little variable across the board. Our big push will be to recover that share over the course of the year in the US toxin space. Hope that helps. Operator: Next, we'll go to the line of Alexandria Hammond from Wolfe Research. Alexandria Hammond: So Skyrizi and Rinvoq have consistently surpassed expectations, but we've been getting some questions on what might drive long term growth in I&I as it relates to these assets. Could you comment on when we should start seeing results from your Skyrizi and Rinvoq combination trials? And as a follow-up, what combination are you most excited about from a mechanistic perspective? Roopal Thakkar: I'll start on the Skyrizi question and the combinations. So the studies have initiated and we would anticipate next year starting to see early data readouts. And I would say we're excited about several of these mechanisms. We've utilized quite a bit of data that we've already collected to see what could be the best combination. And ultimately clinical data will guide that path, but we use biopsy data. The team has applied machine learning, to these data sets, spatial omics, a variety of different techniques. And the ones that we like are one, the alpha-4 beta-7. We think that could be a good combination. We like Lutikizumab, which is a bispecific to anti IL-1 alpha and importantly, IL-1 beta. We see that overexpression in patients with IBD that have failed other advanced therapies. We see something similar for TREM1, which would be another potential combination. And then we as I mentioned, we also have a longer acting an agent designed to be l”